Koji Shinkai - Concepedia

Author

Koji Shinkai

University of Occupational and Environmental Health Japan

Also Known As

K. Shinkai, KOJI SHINKAI, Koji SHINKAI, Koji Shinkai

Publications

702

Citations

H-Index

Concepts

All Affiliations

University of Occupational and Environmental Health Japan

About

Koji Shinkai is an author at University of Occupational and Environmental Health Japan specializing in medicine, psychiatry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	330
2	Social Sciences	5	5	283
3	Biochemistry	1	1	96
4	Diabetes	1	1	42
5	Neurology	1	1	51

Koji Shinkai

Publications

632

Citations

H-Index

Page 1

	Year	Citations
High-Frequency Repetitive Transcranial Magnetic Stimulation Improves Refractory Depression by Influencing Catecholamine and Brain-Derived Neurotrophic Factors Toru Yukimasa, Reiji Yoshimura, Akira Tamagawa, Pharmacopsychiatry	2006	150
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6 Shingo Kakihara, Reiji Yoshimura, Koji Shinkai, International Clinical Psychopharmacology Psychotropic MedicationPsychopharmacologyNeuropsychiatryPharmacotherapyCytochrome P450 2D6	2005	96
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients Reiji Yoshimura, Hikaru Hori, Nobuhisa Ueda, Progress in Neuro-Psychopharmacology and Biological Psychiatry Schizophrenic PatientsPsychiatryPsychotic DisorderPsychopharmacologySchizophrenia	2007	56
Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai, International Clinical Psychopharmacology NeuropsychologyPsychotropic MedicationPsychopharmacologyPlasma HvaNeuropsychiatry	2003	51
Associations Between Baseline Plasma MHPG (3-methoxy-4-hydroxyphenylglycol) Levels and Clinical Responses With Respect to Milnacipran Versus Paroxetine Treatment Koji Shinkai, Reiji Yoshimura, Nobuhisa Ueda, Journal of Clinical Psychopharmacology PsychopathologyPsychopharmacologyPharmacotherapyParoxetine TreatmentSocial Sciences	2004	42
Plasma Levels of Catecholamine Metabolites Predict the Response to Sulpiride or Fluvoxamine in Major Depression N. Ueda, Reiji Yoshimura, Koji Shinkai, Pharmacopsychiatry	2002	39
Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review Reiji Yoshimura, Jun Nakamura, Koji Shinkai, Progress in Neuro-Psychopharmacology and Biological Psychiatry PsychiatryMedicinePsychotropic MedicationDepressionPsychopharmacology	2004	38
Risperidone in the treatment of psychotic depression Makiko Goto, Reiji Yoshimura, Shingo Kakihara, Progress in Neuro-Psychopharmacology and Biological Psychiatry Psychotic DepressionPsychiatryPsychotic DisorderMedicinePsychotropic Medication	2006	35
Successful treatment for obsessive‐compulsive disorder with addition of low‐dose risperidone to fluvoxamine: Implications for plasma levels of catecholamine metabolites and serum brain‐derived neurotrophic factor levels Reiji Yoshimura, Sachiko Kaneko, Koji Shinkai, Psychiatry and Clinical Neurosciences	2006	30
Higher Plasma 5-Hydroxyindoleacetic Acid Levels Are Associated with SSRI-Induced Nausea Nobuhisa Ueda, Reiji Yoshimura, Koji Shinkai, Neuropsychobiology	2003	29

Page 1